{"product_id":"kobayashi-pestle-analysis","title":"Kobayashi PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock strategic clarity with our Kobayashi PESTLE Analysis—concise, expertly researched insights into the political, economic, social, technological, legal, and environmental forces shaping the company’s prospects; purchase the full report to access actionable intelligence, editable tables, and a ready-to-use briefing for investors, consultants, and planners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory oversight of functional foods\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing 2024 red yeast rice incidents, Japan tightened oversight, raising rejection rates for Food with Function Claims from ~8% in 2023 to 18% in 2025, increasing average approval timelines from 45 to 110 days for Kobayashi’s filings.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Kobayashi faces more rigorous safety data and GMP documentation requirements, potentially adding ¥600–900m in annual compliance costs across R\u0026amp;D and regulatory affairs.\u003c\/p\u003e\n\u003cp\u003eThis shift demands continuous engagement with the Consumer Affairs Agency, monthly reporting on adverse events and quarterly renewals to retain licenses for ~120 supplement SKUs sold domestically.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical tensions and supply chain stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKobayashi depends on East Asian trade, with 60% of raw-material imports sourced from China and South Korea; 2024 export revenue from cooling products to the region was ¥24.5bn (≈$170m). Deterioration in Japan–China ties has in past years caused 8–12% supply delays, prompting a political risk plan to diversify routes, increase local sourcing to 35%, and build buffer inventory to protect margins from sanctions or disruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment healthcare cost containment policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Japanese government’s push for self-medication to curb public health spending—part of a policy aiming to reduce annual national health insurance outlays of ¥42 trillion (2024 est.)—aligns with Kobayashi’s OTC-focused model, supporting sales in consumer healthcare where Japan’s OTC market was ¥1.1 trillion in 2023. Continued price-control pressure, however, risks compressing gross margins on essential drugs, where average retail markups have tightened to ~18% in recent years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate governance and transparency reforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical pressure for corporate transparency rose after Kobayashi's management overhaul in late 2024–2025, with the Financial Services Agency citing 28% more disclosure-related inquiries to the sector in 2025 versus 2023 and pushing stricter Corporate Governance Code adherence.\u003c\/p\u003e\n\u003cp\u003eKobayashi must increase independent board seats—aiming for at least 40% independence—and speed disclosures of safety risks; failure risks regulatory scrutiny and loss of government procurement favor worth an estimated ¥12–18bn annually.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025: 28% rise in disclosure inquiries\u003c\/li\u003e\n\u003cli\u003eTarget: ≥40% independent directors\u003c\/li\u003e\n\u003cli\u003ePotential procurement impact: ¥12–18bn\/yr\u003c\/li\u003e\n\u003cli\u003eFSA enforcement: stricter Corporate Governance Code adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational regulatory alignment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs Kobayashi expands in Southeast Asia and North America, aligning with regulators like the FDA and regional bodies is critical; FDA approvals can take 6–18 months and noncompliance risks product holds and recalls that erode revenue.\u003c\/p\u003e\n\u003cp\u003eActive lobbying and participation in trade forums (e.g., ASEAN, USMCA-related committees) can accelerate harmonization; 2024 trade disputes increased regulatory divergence by an estimated 7% in consumer health sectors.\u003c\/p\u003e\n\u003cp\u003eFailure to meet shifting expectations may create market-entry barriers, delaying launches and reducing addressable market share—potentially cutting projected 2026 regional revenues by 10–15%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA approval timelines: 6–18 months\u003c\/li\u003e\n\u003cli\u003e2024 regulatory divergence rise: ~7%\u003c\/li\u003e\n\u003cli\u003ePotential 2026 regional revenue downside: 10–15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory shock ups FWFC rejections to 18%, inflates costs and supply risks for ¥24.5bn sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeightened post-2024 regulation raised Food with Function Claims rejection from ~8% (2023) to 18% (2025), extending approval timelines from 45 to 110 days and adding ¥600–900m\/year compliance costs.\u003c\/p\u003e\n\u003cp\u003eSupply risk: 60% raw imports from China\/Korea, 8–12% delay history; target local sourcing 35% and buffers to protect ¥24.5bn regional cooling-product sales (2024).\u003c\/p\u003e\n\u003cp\u003eGovernance: 28% rise in disclosure inquiries (2025), push to ≥40% independent directors; procurement exposure ¥12–18bn\/yr.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFWFC rejection rate\u003c\/td\u003e\n\u003ctd\u003e18% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproval time\u003c\/td\u003e\n\u003ctd\u003e110 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance cost\u003c\/td\u003e\n\u003ctd\u003e¥600–900m\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw import share\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 export rev (region)\u003c\/td\u003e\n\u003ctd\u003e¥24.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisclosure inquiries rise\u003c\/td\u003e\n\u003ctd\u003e28% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement risk\u003c\/td\u003e\n\u003ctd\u003e¥12–18bn\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect the Kobayashi across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with each section backed by current data and trends to identify threats and opportunities for executives, consultants, and entrepreneurs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe Kobayashi PESTLE Analysis provides a clean, summarized view of external factors, visually segmented by category for quick interpretation and easily droppable into presentations or shared across teams for fast alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency volatility and the Japanese Yen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Yen's valuation against the USD and EUR is a key driver for Kobayashi's export-heavy segments; a 5% Yen depreciation in 2024 lifted repatriated revenue by roughly JPY 4.2bn for comparable exporters. While a weaker Yen enhances reported overseas sales, it raised imported raw ingredient and energy costs—Japan's 2024 import fuel bill rose ~12% YoY—pressuring margins. Kobayashi needs advanced FX hedging: rolling forwards, currency options and natural hedges to stabilize consolidated earnings against volatility. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressure on manufacturing costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal inflation pushed logistics, packaging and chemical precursor costs up roughly 12–18% by end-2025, squeezing Kobayashi’s margins; management must decide whether to pass increases to consumers or absorb them to protect share. Domestic price elasticity is high, so passing full hikes risks volume decline of 3–6%. To sustain profitability, Kobayashi targets manufacturing cost cuts of 8–10% via automation and supplier renegotiation. Failure to cut costs could compress operating margin by 150–250 basis points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer spending power in the domestic market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJapan's real wages fell 0.1% in 2024 even as CPI rose ~2.6%, creating cautious spending on non-essential health products; Kobayashi must position items as daily necessities to sustain volume. In 2024 consumers shifted toward private-labels—market share gains of ~1–2ppt in OTC health categories—so Kobayashi needs clear differentiation and value-per-dose messaging to avoid trade-downs during downturns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth opportunities in emerging markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpwith japan aging population flattening domestic demand kobayashi revenue growth increasingly depends on expansion into emerging markets where gdp averages in southeast asia despite lower per-capita spending indonesia and vietnam investing localized production reduces logistics costs down per unit estimated enables price-competitive positioning. local plants also mitigate tariff risks improve time-to-market for region-specific skus supporting projected regional sales cagr of by\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh SE Asia GDP growth 4.5–6.0% (2024)\u003c\/li\u003e\n\u003cli\u003eLocal production cuts shipping cost ~15–25%\u003c\/li\u003e\n\u003cli\u003eExpected regional sales CAGR ~12% to 2028\u003c\/li\u003e\n\u003cli\u003eLower per-capita spend but larger population base\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pwith\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of the 2024 recall on market valuation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe 2024 red yeast rice recall caused Kobayashi's stock to drop about 28% from April to December 2024, and negative investor sentiment persisted into 2025 with average daily traded volume down 18% year-over-year.\u003c\/p\u003e\n\u003cp\u003eThe company allocated ¥12.4 billion to compensation and legal reserves by Q3 2025, reducing cash and equivalents by roughly 22% and tightening short-term liquidity ratios.\u003c\/p\u003e\n\u003cp\u003eRestoring investor confidence is a priority to secure capital for R\u0026amp;D; management targets a return to pre-recall net cash levels and aims to raise ¥8–10 billion through equity or convertible debt by late 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStock decline ~28% (Apr–Dec 2024)\u003c\/li\u003e\n\u003cli\u003eTrading volume -18% YoY into 2025\u003c\/li\u003e\n\u003cli\u003e¥12.4B reserved for compensation\/legal\u003c\/li\u003e\n\u003cli\u003eCash down ~22%; ¥8–10B capital target\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWeak yen lifts repatriation but squeezes margins; SE Asia expansion targets ~12% CAGR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe weak Yen boosted repatriated revenue (~JPY 4.2bn per 5% depreciation in 2024) but raised import costs as Japan's 2024 fuel\/import bill +12% YoY, squeezing margins; management targets 8–10% manufacturing cuts and advanced FX hedging. Domestic demand is price-sensitive after 2024 real-wage decline and private-label gains, while SE Asia expansion (GDP ~4.5–5.5% in 2024) and localized plants support a ~12% regional sales CAGR to 2028.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eYen effect (est.)\u003c\/td\u003e\n\u003ctd\u003eJPY 4.2bn per 5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan import fuel bill 2024\u003c\/td\u003e\n\u003ctd\u003e+12% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget manufacturing cuts\u003c\/td\u003e\n\u003ctd\u003e8–10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSE Asia GDP 2024\u003c\/td\u003e\n\u003ctd\u003e4.5–5.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional sales CAGR to 2028\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eKobayashi PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Kobayashi PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic planning and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751743631737,"sku":"kobayashi-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/kobayashi-pestle-analysis.png?v=1772234430","url":"https:\/\/growthsharematrix.com\/products\/kobayashi-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}